secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001104659-25-001873
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium provides 2025 guidance: product revenue $735M-$750M, adj EBITDA $435M-$450M
--------------------------------------------------------------------------------

- Product revenues, net expected $735M-$750M for 2025.
- Jornay PM net revenue expected >$135M in 2025.
- Adjusted EBITDA (excl. SBC) expected $435M-$450M.
- Adjusted operating expenses (excl. SBC) expected $220M-$230M.
- Repurchased $60M in shares in 2024 under $150M buyback program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465925001873/0001104659-25-001873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465925001873/tm252196d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-001873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer